General
Preferred name
CHLOROPYRAMINE
Synonyms
CHLOROPYRAMINE HYDROCHLORIDE ()
Avapena ()
Nilfan ()
Alergosan ()
Halopyramine hydrochloride ()
Halopyramine ()
C4 ()
CHLORPYRAMIN HYDROCHLORIDE ()
Cloropiramina ()
NSC-241038 ()
P&D ID
PD009208
CAS
6170-42-9
59-32-5
10458-04-5
Tags
available
drug
Drug Status
approved
experimental
investigational
Max Phase
2.0
Drug indication
Pruritus
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Chloropyramine hydrochloride is a histamine receptor H1 antagonist which can also inhibit the biochemical function of VEGFR-3 and FAK.
PRICE
29
PHARMACODYNAMICS
Chlorpyramine is a competitive reversible H1 receptor antagonist. This inhibits vasodilation, increases in vascular permeability, and tissue edema associated with histamine release. In addition, chloropyramine has some anticholinergic properties. These effects, along with its ability to pass through the blood-brain barrier lead to side effects such as drowsiness, weakness, vertigo, fatigue, dryness in the mouth, constipation, and rarely - visual disturbances and increase of intraocular pressure.
DESCRIPTION
Chloropyramine hydrochloride (Alergosan) is a histamine receptor H1 antagonist.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Halopyramine is known as a competitive reversible H1-receptor antagonist. It exerts its pharmacological action by competing with histamine for the H1 subtype histamine receptor. It inhibits the vasodilation, increased vascular permeability, and tissue edema associated with histamine release in the tissue by blocking the effects of histamine. It is a first generation antihistamine drug for the treatment of allergic rhinitis, allergic conjunctivitis, bronchial asthma, and other allergic conditions. It has been listed.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
10
Organisms
0
Compound Sets
15
BOC Sciences Bioactive Compounds
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugCentral
DrugCentral Approved Drugs
DrugMatrix
IPPI - DB
MedChem Express Bioactive Compound Library
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
49
Molecular Weight
289.13
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
0
Rotatable Bonds
6
Ring Count
2
Aromatic Ring Count
2
cLogP
3.3
TPSA
19.37
Fraction CSP3
0.31
Chiral centers
0.0
Largest ring
6.0
QED
0.81
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Angiogenesis
Cytoskeletal Signaling
GPCR/G protein
Immunology/Inflammation
Neuroscience
Tyrosine Kinase/Adaptors
Neuronal Signaling
Protein Tyrosine Kinase/RTK
Target
Ligand for Target Protein
HRH1
FAK
Histamine Receptor
VEGFR
FAK-VEGFR-3
H1 receptor
Indication
edema, conjunctivitis, allergic rhinitis, asthma
Disease Area
cardiology, ophthalmology, allergy, pulmonary
MOA
Histamine Receptor antagonist
Solubility
Soluble in DMSO, not in water
Source data
